Moderna (NASDAQ: MRNA) investors didn't need to have too much patience in the early days of the pandemic. The company brought its coronavirus vaccine candidate from drawing board to market in about nine months. Next year, though, Moderna investors may need to rely on their patience.
In the early days of the pandemic, investors bet Novavax (NASDAQ: NVAX) would be a coronavirus vaccine winner. When the biotech's vaccine candidate fell behind, though, investors lost faith. With its shares down almost 90% this year, you may be wondering if Novavax presents a great buying opportunity.
Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.